These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 9607859

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue.
    Cohen OJ, Pantaleo G, Holodniy M, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT.
    Proc Natl Acad Sci U S A; 1995 Jun 20; 92(13):6017-21. PubMed ID: 7597072
    [Abstract] [Full Text] [Related]

  • 25. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.
    Rey D, Hughes M, Pi JT, Winters M, Merigan TC, Katzenstein DA.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar 01; 17(3):203-8. PubMed ID: 9495218
    [Abstract] [Full Text] [Related]

  • 26. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
    Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, Merigan TC.
    J Virol; 1996 Feb 01; 70(2):1086-90. PubMed ID: 8551567
    [Abstract] [Full Text] [Related]

  • 27. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine.
    Edelstein RE, Nickerson DA, Tobe VO, Manns-Arcuino LA, Frenkel LM.
    J Clin Microbiol; 1998 Feb 01; 36(2):569-72. PubMed ID: 9466779
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Feb 01; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 30. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.
    Lafeuillade A, Poggi C, Chadapaud S, Hittinger G, Chouraqui M, Pisapia M, Delbeke E.
    J Acquir Immune Defic Syndr; 2001 Jan 01; 26(1):44-55. PubMed ID: 11176268
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection.
    Poggi C, Profizi N, Djediouane A, Chollet L, Hittinger G, Lafeuillade A.
    AIDS; 1999 Jul 09; 13(10):1213-20. PubMed ID: 10416525
    [Abstract] [Full Text] [Related]

  • 33. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
    Kojima E, Shirasaka T, Anderson BD, Chokekijchai S, Steinberg SM, Broder S, Yarchoan R, Mitsuya H.
    J Infect Dis; 1995 May 09; 171(5):1152-8. PubMed ID: 7751690
    [Abstract] [Full Text] [Related]

  • 34. Additional mutations detected in sequential HIV-1 isolates from ZDV-treated patients.
    Magierowska-Jung M, Agut H, Katlama C, Autran B, Huraux JM.
    J Med Virol; 1997 Jan 09; 51(1):48-55. PubMed ID: 8986949
    [Abstract] [Full Text] [Related]

  • 35. Kinetics of viral clearance in plasma, peripheral blood mononuclear cells and lymph nodes.
    Lafeuillade A, Djediouane A, Poggi C, Profizi N, Costes O, Tamalet C.
    AIDS; 1996 Jun 09; 10(7):801-2. PubMed ID: 8805878
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients.
    Yerly S, Denereaz N, Mermillod B, Hirschel B, Perrin L.
    Antivir Ther; 1996 Aug 09; 1(3):167-71. PubMed ID: 11322250
    [Abstract] [Full Text] [Related]

  • 38. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA.
    Kaye S, Comber E, Tenant-Flowers M, Loveday C.
    AIDS Res Hum Retroviruses; 1995 Oct 09; 11(10):1221-5. PubMed ID: 8573378
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MM.
    J Infect Dis; 2000 Feb 09; 181(2):491-7. PubMed ID: 10669331
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.